Resumen:
Introduction: Pathogenesis of Chagas disease (CD) caused by the protozoan parasite Trypanosoma cruzi
(T. cruzi) involves chronic oxidative and inflammatory stress. In this review, we discuss the research
efforts in therapeutic vaccine development to date and the potential challenges imposed by oxidative
stress in achieving an efficient therapeutic vaccine against CD.
Areas covered: This review covers the immune and nonimmune mechanisms of reactive oxygen
species production and immune response patterns during T. cruzi infection in CD. A discussion on
immunotherapy development efforts, the efficacy of antigen-based immune therapies against T. cruzi,
and the role of antioxidants as adjuvants is discussed to provide promising insights to developing
future treatment strategies against CD.
Expert opinion: Administration of therapeutic vaccines can be a good option to confront persistent
parasitemia in CD by achieving a rapid, short-lived stimulation of type 1 cell-mediated immunity. At the
same time, adjunct therapies could play a critical role in the preservation of mitochondrial metabolism
and cardiac muscle contractility in CD. We propose combined therapy with antigen-based vaccine and
small molecules to control the pathological oxidative insult would be effective in the conservation of
cardiac structure and function in CD.